Trial intelligence / Profile preview

Phase 2a observer-blind randomized study of multivalent mRNA seasonal influenza vaccine candidates in adults

2025-522599-97-00Phase 2Completed

Sponsor: GSK
Start: Oct 2025
Modality: Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
Countries: 2

Overview

Phase 2, randomised, single-blind trial of GSKVX000000034798, GSKVX000000048110, GSKVX000000048111, GSKVX000000070248, GSKVX000000070250 and 2 more in influenza (2 arms), sponsored by GSK. Primary endpoints: Antigen 1 antibody immunogenicity at Day 29 and Safety and reactogenicity. Started Oct 2025; status: completed.

Drugs

GSKVX000000034798GSKVX000000048110GSKVX000000048111GSKVX000000070248GSKVX000000070250

Conditions

influenza

Beyond the preview

Go deeper on 2025-522599-97-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2025-522599-97-00.